Xbrane Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- Xbrane Biopharma's estimated annual revenue is currently $19.2M per year.
- Xbrane Biopharma's estimated revenue per employee is $155,000
Employee Data
- Xbrane Biopharma has 124 Employees.
- Xbrane Biopharma grew their employee count by 39% last year.
Xbrane Biopharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 99 | -49% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.5M | 29 | -6% | N/A | N/A |
#10 | $9.6M | 62 | -7% | N/A | N/A |
What Is Xbrane Biopharma?
Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology.
keywords:N/AN/A
Total Funding
124
Number of Employees
$19.2M
Revenue (est)
39%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Xbrane Biopharma News
Xbrane Biopharma is not a large company by global standards. It has a market capitalization of kr2.2b, which means it wouldn't have the...
Debiopharm Group; Ipsen; Xbrane Biopharma; Chengdu Tiantaishan Pharmaceutical; Arbor Pharmaceuticals; Ferring. Triptorelin Drug Market Breakdown by Type: 3.75...
Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $36M | 124 | 53% | N/A |
#2 | $15.1M | 126 | 56% | N/A |
#3 | $15.1M | 126 | 56% | N/A |
#4 | $15.1M | 126 | 56% | N/A |
#5 | $26.7M | 127 | 51% | N/A |